GenetikaPlus Ltd. (NeuroKaire)

www.neurokaire.com

Formerly Genetika RX

High-Tech Company

TECH VERTICALS

Artificial Intelligence, Biotechnology, Computer Vision, Deep Learning, Digital Health, Healthcare IT, Impact, Insurtech, MedTech, Mental Health, Neuroscience, Personalized Medicine, Pharmaceuticals, Stem Cells

General Data

Sector	Biomed
Company Stage:	Initial Revenues
Established	2017
Number of Employees	47
Employees in Israel	26
Reg. Number:	abCDe

DESCRIPTION

NeuroKaire is an operator of a medical platform, intended to transform brain health and eliminate suffering precision medicine in psychiatry and neurology. The company's innovative technology also provides pharmaceutical companies with essential tools for targeted drug discovery and development, enabling clinicians to identify the optimal antidepressant based on the unique response of a patient's brain cells combined with their genetics and medical history. Recently, the company released BrightKaire - an innovative blood test based on extracting brain cells from a simple blood sample and exposing them to various drugs, while analyzing the response using AI and genetic information. Its that it does not settle for indirect prediction, but directly tests the response of the patient's own brain cells to various drugs, thus enabling a truly functional and precise adjustment of drug treatment. The use of the test is expected to save time, since finding the right drug today is done through trial and error that can take up to two years and reduce unnecessary suffering and side effects.

TECHNOLOGY

NeuroKaire utilizes advanced stem cell technology, machine learning and data analysis to predict drug responses for Central Nervous System (CNS) disorders. The company transforms patient blood cells into neurons, meticulously analyzing their morphological and genetic features using sophisticated deep learning algorithms to identify biomarkers associated with treatment outcomes. By integrating these biomarkers with patient history data, NeuroKaire provides a personalized approach to medication selection, enhancing treatment efficacy and minimizing side effects for individuals with CNS disorders.

Products and Phases

Product	Phase
NeuroKaire; StemifAI	Approved CE Approved CLIA
NeuroKaire helps healthcare providers prescribe the most effective medications, leading to faster recovery, reduced side effects, and lower drug dosages.

	TARGET MARKETS
	Healthcare providers psychiatrists, pharmaceutical and insurance companies, telemedicine providers, pharma sector, research institutions, patients with CNS disorders.

	BUSINESS MODEL
	B2B

COMPETITORS

Genomind , Genesight , Neuropharmagen

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm
abC Defghij	Patent Attorneys

CONTACT INFO

Expand / Collapse All

Main Address: Tel Aviv, Israel

Address	126 Yigal Alon St., Building C, 2nd Floor
City	Tel Aviv
Country	Israel
Zip	6744332

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: United States

Address	78 John Miller Way, Suite #420, Kearny
State/Province	NJ
Country	United States
Zip	07032

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: United States

State/Province	DE
Country	United States

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Dr. Talia Cohen-Solal	CEO & Co-Founder
Dr. Daphna Laifenfeld	CSO & Co-Founder	Ibex (Chief Strategy Officer)
Mr. Elad Bibi-Aviv	COO
Mr. Issar Yazbin	CPO	Ibex (VP, Product Management)
Dr. Orit Goldman	VP, Biology	Betalin (Head of R&D Laboratory)
Mr. David Pattison	VP, Business Development	EY Israel (Global Business Development Executive & Senior Manager)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Co-Founder, GreyBird Ventures
abC Defghij	Board Member	CEO & Co-Founder, NeuoKaire
abC Defghij	Board Member	CSO & Co-Founder, NeuoKaire
abC Defghij	Board Member	Managing Partner & Founder, GreyBird Ventures
abC Defghij	Observer	Managing Partner & Co-Founder, Meron Capital
abC Defghij	Observer	Managing Partner & Founder, Jumpspeed Ventures

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round - Extended

Apr. 30, 2024

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe

First Round

Sep. 30, 2021

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe	Led the round
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Seed

Oct. 01, 2019

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jul. 31, 2022

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jun. 01, 2020

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Dec. 01, 2018

Initial Revenues

Contributor	Type	Amount	Remarks
abC Defghij	Innovation Lab	abCDe

Non-Equity Assistance

Apr. 23, 2018

Seed

Contributor	Type	Amount	Remarks
abC Defghij	General Accelerator	abCDe

Non-Equity Assistance

Nov. 28, 2017

Seed

Contributor	Type	Amount	Remarks
abC Defghij	General Accelerator	abCDe

Last Updated:	abCDe
IVC Number:	abCDe